2015 zhong guo sheng wu zhi pin nian hui zuo di shi wu ci quan guo sheng wu zhi pin xue shu yan tao hui hui yi tong zhi ( di yi lun )

..............page:1792

2015 zhong guo sheng wu zhi pin nian hui zuo di shi wu ci quan guo sheng wu zhi pin xue shu yan tao hui zheng wen tong zhi ( di er lun )

..............page:1794

zhong guo xin yao za zhi zai jing ju ban yao xue lun wen xie zuo pei xun jiang zuo

..............page:1798

New trends in the strategy of research and development of new drug in the post-financial-crisis era
FENG Ren-tian;BAI Hua;Zhejiang Hisun Pharmaceutical Co.;Ltd.;

..............page:1801-1805

nuo hua kang ai yao odomzo huo ou meng pi zhun zhi liao ju bu wan qi ji di xi bao ai

..............page:1805

Competition between originator and generic drugmakers from olmesartan patent
FU Jing;LIU Jun-zheng;Patnet Examination Cooperation Center of the Patent Office;State Intellectual Property Office;

..............page:1806-1809+1819

Development and prospect on the marketed drug sampling and testing for quality evaluation
ZHU Jia-liang;YANG Xia;LI Zhe-yuan;ZHU Jiong;National Institutes for Food and Drug Control;Henan Provincial Institutes for Food and Drug Control;Yunnan Provincial Institutes for Food and Drug Control;

..............page:1810-1815

Considerations about clinical research strategy of cardiac safety for QT internal prolongation induced by new non-antiarrhythmic drugs in China
GENG Ying;ZHAO Deng-heng;YANG Huan;YANG Zhi-min;Centre for Drug Evaluation;State Food and Drug Administration;

..............page:1816-1819

Predication and application of targeted antitumor agents based on precision medicine
ZHANG Hui-xian;HE Qi-yang;Institute of Medicinal Biotechnology;Chinese Academy of Medical Sciences and Peking Union Medical College;

..............page:1820-1824+1830

Assay of potency for Xuezhikang by inhibiting HMG-CoA reductase
WANG Jing;WANG Qing;SUN Ji-ye;SHA Chun-jie;DUAN Zhen-wen;LIU Wan-hui;School of Pharmacy;Yantai University;State Key Laboratory of Long-acting and Targeting Drug Delivery System;Luye Pharma Group Ltd.;Beijing Peking University WBL Biotech Co.;Ltd.;

..............page:1825-1830

A brief overview of regulations and research methods of drug non-clinical dependence evaluation
JIANG Wei-ning;DONG Yan-sheng;JIANG Tao;WANG Xiao-fei;WANG Quan-jun;School of Chinese Material Medica;Guangdong Pharmaceutical University;State Key Laboratory of Medical Countermeasures and Toxicology;National Beijing Center for Drug Safety Evaluation and Research;Institute of Pharmacology and Toxicology;Academy of Military Medical Sciences;Center of Laboratorial Animals;Guangdong Pharmaceutical University;

..............page:1831-1837

Normalization of registration testing information of imported monoclonal antibody-based biotherapeutics
CHEN Yu-qin;LIU Chun-yu;GUO Wei;WANG Lan;GAO Kai;Chinese National Institute for Food and Drug Control;

..............page:1838-1842+1855

Advances in the chemical substances illegally adulterated in traditional Chinese medicines and health foods
XU Shuo;JIN Peng-fei;XU Qiao-ling;L Xiao-chuan;HE Xiao-rong;Department of Pharmaceutical Science;Beijing Hospital;Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation;Health Care Division;Security Bureau of the General Staff;

..............page:1843-1850

Technologies of Raman spectroscopy and its applications in drug research
REN Xiao-dan;LUO Xiang;FENG Hui;ZHONG You-quan;YIN Xiao-ying;Jiangxi University of Traditional Chinese Medicine College of Pharmacy;Analytical and Testing Research Institute of Jiangxi Province;

..............page:1851-1855

Current status of molecular targeted drugs for EML4-ALK-positive non-small cell lung cancer
DU Ping;LIU Li-hong;Department of Pharmacy;Beijing Chao-yang Hospital;Capital Medical University;

..............page:1856-1861

Minimization methods of subjects’ risk management approach to drug clinical trials
WEN Ke;WANG Jin;BAI Nan;WANG Rui;Translational Medical Center;PLA General Hospital;

..............page:1862-1866

Introduction on Guideline on the evaluation of medicinal products for the treatment of chronic constipation by EMA Committee for Medicinal Products for Human Use( CHMP)
YAN Yu-jia;HU Si-yuan;YANG Na;JIN Li;Tianjin University of Traditional Chinese Medicine;First Hospital of Tianjin University of TCM;

..............page:1867-1869

Long-term toxicity of Xinnaoning capsule in SD rats
LU Guo;XU Yang-mei;JI Hui;Department of Pharmacology;China Pharmaceutical University;

..............page:1870-1875

Synthesis of trelagliptin succinate
JIANG Jie-ying;YOU Li;DENG Si-si;DENG Jun-feng;LIU Yu;ZHANG Xiao;Sichuan Industrial Institute of Antibiotics;

..............page:1876-1878+1910

Preparation of nano-sized ATP-Gd and its application in magnetic resonance imaging
XU Yun-jun;JIN Qin-yu;YANG Dong-mei;Department of Radiology;Anhui Provincial Hospital;

..............page:1879-1882

Preparation and physicochemical property of furanodiene liposomes
CHEN Ning;YANG Jing;JIANG Wei-hua;SUN Lin-lin;WANG Lin;WANG Dong-kai;YIN Dong-er;Shenyang Pharmaceutical University;Center for Drug Evaluation and Certification of Hainan Province;Hainan Bikai Pharmaceutical Co.;Ltd.;

..............page:1883-1889

An HPLC method for determining related substances in clevidipine butyrate fat emulsion injection
MA Hai-bo;ZHAO Jing;LI Zhong-li;Beijing Research Institute of Shanxi PUDE Pharmaceutical Co.;Ltd.;

..............page:1890-1896+1915

HPLC fingerprints of Penyanling granules
XIAO Zuo-qi;PAN Tao;OUYANG Bo;HUANG Yi;TIAN Xia;WEN Xiao-ke;The Maternal and Child Health Hospital of Hunan Province;

..............page:1897-1901

2015 quan guo yao wu liu xing bing xue xue shu nian hui zuo xue ke fa zhan 20 zhou nian hui gu hui yi tong zhi ( di yi lun )

..............page:1901

Identification of related substances in capecitabine by LC-MS
ZHANG Ge;LIU Chao-yi;CHEN Lei-lin;HANG Tai-jun;SONG Min;Department of Pharmaceutical Analysis;China Pharmaceutical University;

..............page:1902-1910

Effect of various drying methods on the quality of Wulong granule extracts
GU Yong-jun;WANG Guang-wei;WANG Li;SONG Xiang-rong;State Key Laboratory of Biotherapy;Sichuan University;Pharmaceutical Factory of Chengdu Huasun Group Co.;Ltd.;

..............page:1911-1915

Progress in therapeutic drug monitoring and rational use of anti-tumor drugs
LIU Jing-tao;ZHANG Yan-hua;Key Laboratory of Carcinogenesis and Translational Research;Pharmacy Department;Peking University Cancer Hospital;

..............page:1916-1920